• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Accuray CEO: TomoTherapy integration starting to take shape

Accuray CEO: TomoTherapy integration starting to take shape

March 15, 2011 By MassDevice staff

ARAY logo

Accuray Inc.’s (NSDQ:ARAY) nearly $300 million deal to buy TomoTherapy Inc. (NSDQ:TOMO) isn’t closed yet, but the integration of the two companies is already underway.

Accuray CEO Euan Thomson wrote in an email to employees that the company isn’t officially beginning the process until the deal closes, but the Sunnyvale, Calif.-based CyberKnife radiosurgery device maker is already taking steps to ensure a smooth transition.

“As you know, we held All Hands meetings at Accuray early in the week, and I am currently traveling to each regional headquarters to meet with as many of you as possible,”Thomson wrote.. “I am really pleased by your positive reaction to the news. I have heard that reception of the news at TomoTherapy has been generally positive as well. People in both companies share a passion for patient care and a pride in the breakthrough technologies that we have developed.”

The company plans to hire an integration consulting firm to “provide the specialized expertise needed to ensure we develop a comprehensive integration plan,” he added.

Accuray will also form a joint integration team to plan the merging of the two companies and then begin the process once the plan is in place.

Thomson gave no indication of the timeline for the transition, or how many employees might be laid off if redundancies are found. The two firms have set up a special website for the transition at www.AccurayTomoTherapy.com.

Accuray announced that it had signed an agreement to buy TomoTherapy for $4.80 per share in cash and stock March 7. The purchase price was a nearly 31 percent premium over TOMO’s $3.67 closing price Friday, March 4.

The companies believe their technologies complement with overlapping patient populations.

TomoTherapy’s "ring gantry-based" cancer treatment platform is designed to reduce radiation exposure to surrounding tissue surrounding cancerous cells. The system uses CT imaging to guide conformal radiation therapy treatments.

"This transformational transaction significantly increases our global market presence, creates financial benefits from operating efficiencies and overhead reductions, and creates exciting new revenue opportunities for us. The combined company will also have greater scale to invest in the R&D that will keep it on the leading edge of innovation, offering new hope for cancer patients worldwide," Thomson said at the time.

Filed Under: Mergers & Acquisitions, News Well Tagged With: Accuray Inc., TomoTherapy Inc.

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy